Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 3ive Labs
- 入组人数
- 124
- 试验地点
- 8
- 主要终点
- Mean Peak Percent Change in Serum Creatinine
研究概览
简要总结
Patients with renal insufficiency who undergo cardiac surgery with cardiopulmonary bypass (CPB) are at significant risk for exacerbation of renal dysfunction postoperatively. This in turn is associated with an increased risk of prolonged intensive care unit (ICU) length of stay, other comorbidities including surgical complications and 30-day mortality. Renal impairment is generally identified based on an increase in serum creatinine concentration and/or a certain magnitude decrease in estimated glomerular filtration rate (eGFR).
The JuxtaFlow® Renal Assist Device (RAD) is designed to sustain or enhance glomerular filtration perioperatively for patients with renal insufficiency by applying a mild controlled negative pressure to the collecting system via the renal pelvis, thereby increasing effective filtration pressure and reducing tubular pressure. This mechanism is designed to support the kidneys' functions during times of renal stress that would be associated with intrarenal edema, volume overload, increased venous pressure, and inflammatory response. By supporting renal function, specifically during the acute stress of CPB, JuxtaFlow holds promise to protect nephron function, decrease renal hypoxia, and provide multifactorial kidney function support to maintain their ability to manage future stress.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 22 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •To be eligible for participation in this study, an individual must meet all the following criteria:
- •A candidate for elective or urgent on-pump coronary artery bypass grafting (CABG) and/or valvular surgery
- •Male or Female age 22 to 85 years
- •Estimated glomerular filtration rate (eGFR) 15 - 60 mL/min/1.73m2
- •Signed and dated informed consent
- •Female patients of childbearing potential must:
- •have negative pregnancy test at the informed consent visit,
- •be using previously initiated approved and effective contraception from the informed consent visit through completion of the study *The only recommended contraception is condoms.
排除标准
- •An individual who meets any of the following criteria will be excluded from participation in this study:
- •Any individual, or their legally authorized representative (LAR), who does not understand the requests and risks of participating in the clinical trial or is unable to give informed consent
- •Pregnancy or lactation
- •Prior cardiac surgery within the last 6 months
- •Hemodynamic instability as determined by the Principal Investigator
- •Immunosuppression
- •Active infections (e.g. HIV, Tbc, and all types of Hepatitis)
- •History of polycystic kidney disease
- •Patients with only one active kidney or one poorly functioning kidney
- •Evidence of current kidney obstruction (e.g., Kidney stones)
- •Evidence of current hydronephrosis
- •Active upper and/or lower urinary tract infections
- •Malignancy; oncological Surgery within 5 years or ongoing antitumoral treatment
- •Ongoing sepsis or endocarditis
- •Patients who have an expected 30-day postoperative mortality greater than 10% as determined by the Principal Investigator
- •Any secondary condition as determined by the investigator that would place the subject at an increased risk or preclude the subject's full compliance with the study procedures, including injuries to the urinary organs and/or external genitals; or severe BPH
- •Unexplained/unexpected gross hematuria as determined by the Investigator
- •Current or planned treatment with an investigational drug (IND), device (IDE), or other investigational intervention within 3 months prior to or during participation in this clinical trial
- •Patients who have a current unrepaired ureteral avulsion as determined by the investigator
- •Patients otherwise contraindicated for urological interventions, including ureter guidewire placement via bladder cystoscopy and ureteral catheterization, or otherwise contraindicated for any of the other study procedures
研究组 & 干预措施
Standard of Care
A standard bladder catheter (i.e. Foley) will be placed for bladder urine collection peri-operatively for up to 72 hours while in critical care. No JuxtaFlow catheters will be placed in control subjects.
Renal Assist Device
Subjects randomized to the Treatment group will receive up to 72 hours of controlled negative pressure (-15mmHg) into the renal pelvis of each kidney. Treatment will be discontinued when the subject is transferred out of critical care after at least 24 hours of treatment. A standard bladder catheter (i.e. Foley) will also be placed for bladder urine collection peri-operatively for up to 72 hours.
干预措施: Renal assist device (Device)
结局指标
主要结局
Mean Peak Percent Change in Serum Creatinine
时间窗: 96 hours peri-operative
The mean peak percent change in serum creatinine from baseline values (prior to treatment) within the first 96 hours post-surgery for JuxtaFlow treated subjects as compared to controls.
Incidence of Treatment-Emergent Adverse Events
时间窗: From enrollment to post-operative day 30
The characterization and comparison of all types, frequency, and severity of adverse events (AEs) associated with JuxtaFlow treatment and controls.
次要结局
- AUC Serum Creatinine(96 hours peri-operative)
- AKI incidence(From post-operative day 1 to 14)
- Creatinine Clearance(24 to 48 hours post-operatively)
- Critical Care Length of Stay(through study study completion, an average of 1 year)